Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity
Phase of Trial: Phase I/II
Latest Information Update: 02 Dec 2016
Price : $35 *
At a glance
- Drugs Tolcapone (Primary)
- Indications Amyloid polyneuropathy
- Focus Pharmacodynamics; Proof of concept
- Sponsors SOM Biotech
- 31 Aug 2018 Biomarkers information updated
- 29 Nov 2016 Status changed from recruiting to completed.
- 21 Apr 2016 Results of Phase IIa part (n=21) presented at the 68th Annual Meeting of the American Academy of Neurology.